$74.79
Live
0.13%
Downside
Day's Volatility :2.35%
Upside
2.22%
5.42%
Downside
52 Weeks Volatility :27.79%
Upside
23.66%
Period | Haemonetics Corp | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -15.62% | 3.6% | 0.0% |
6 Months | -8.93% | 10.2% | 0.0% |
1 Year | -14.15% | 19.6% | 0.0% |
3 Years | 6.31% | 16.8% | -23.0% |
Market Capitalization | 3.9B |
Book Value | $17.70 |
Earnings Per Share (EPS) | 2.23 |
PE Ratio | 34.05 |
PEG Ratio | 1.22 |
Wall Street Target Price | 109.8 |
Profit Margin | 8.61% |
Operating Margin TTM | 19.64% |
Return On Assets TTM | 6.09% |
Return On Equity TTM | 12.98% |
Revenue TTM | 1.3B |
Revenue Per Share TTM | 26.26 |
Quarterly Revenue Growth YOY | 8.0% |
Gross Profit TTM | 530.8M |
EBITDA | 314.1M |
Diluted Eps TTM | 2.23 |
Quarterly Earnings Growth YOY | -0.07 |
EPS Estimate Current Year | 3.96 |
EPS Estimate Next Year | 4.4 |
EPS Estimate Current Quarter | 1.0 |
EPS Estimate Next Quarter | 1.09 |
What analysts predicted
Upside of 46.81%
FY19 | Y/Y Change | |
---|---|---|
Revenue | 967.6M | ↑ 7.04% |
Net Income | 55.0M | ↑ 20.73% |
Net Profit Margin | 5.69% | ↑ 0.65% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 988.5M | ↑ 2.16% |
Net Income | 76.5M | ↑ 39.09% |
Net Profit Margin | 7.74% | ↑ 2.05% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 870.5M | ↓ 11.94% |
Net Income | 79.5M | ↑ 3.85% |
Net Profit Margin | 9.13% | ↑ 1.39% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 993.2M | ↑ 14.1% |
Net Income | 43.4M | ↓ 45.42% |
Net Profit Margin | 4.37% | ↓ 4.76% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 1.2B | ↑ 17.67% |
Net Income | 115.4M | ↑ 166.05% |
Net Profit Margin | 9.87% | ↑ 5.5% |
FY24 | Y/Y Change | |
---|---|---|
Revenue | 1.3B | ↑ 12.01% |
Net Income | 117.6M | ↑ 1.87% |
Net Profit Margin | 8.98% | ↓ 0.89% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 304.4M | ↓ 0.29% |
Net Income | 29.4M | ↓ 10.81% |
Net Profit Margin | 9.65% | ↓ 1.14% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 311.3M | ↑ 2.27% |
Net Income | 41.0M | ↑ 39.68% |
Net Profit Margin | 13.18% | ↑ 3.53% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 318.2M | ↑ 2.2% |
Net Income | 24.9M | ↓ 39.31% |
Net Profit Margin | 7.83% | ↓ 5.35% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 336.3M | ↑ 5.68% |
Net Income | 31.2M | ↑ 25.43% |
Net Profit Margin | 9.29% | ↑ 1.46% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 343.3M | ↑ 2.09% |
Net Income | 20.4M | ↓ 34.81% |
Net Profit Margin | 5.93% | ↓ 3.36% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Revenue | 336.2M | ↓ 2.07% |
Net Income | 38.4M | ↑ 88.41% |
Net Profit Margin | 11.41% | ↑ 5.48% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 1.3B | ↑ 3.02% |
Total Liabilities | 606.9M | ↑ 25.16% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 1.3B | ↓ 0.6% |
Total Liabilities | 680.0M | ↑ 12.05% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 1.8B | ↑ 43.63% |
Total Liabilities | 1.1B | ↑ 60.04% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 1.9B | ↑ 2.19% |
Total Liabilities | 1.1B | ↑ 2.03% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 1.9B | ↑ 4.04% |
Total Liabilities | 1.1B | ↑ 0.59% |
FY24 | Y/Y Change | |
---|---|---|
Total Assets | 2.2B | ↑ 13.48% |
Total Liabilities | 1.2B | ↑ 10.64% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 1.9B | ↑ 3.02% |
Total Liabilities | 1.1B | ↑ 1.34% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 2.0B | ↑ 1.42% |
Total Liabilities | 1.1B | ↓ 1.72% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 2.0B | ↑ 2.5% |
Total Liabilities | 1.1B | ↑ 1.82% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 2.2B | ↑ 9.4% |
Total Liabilities | 1.3B | ↑ 12.48% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 2.2B | ↓ 0.22% |
Total Liabilities | 1.2B | ↓ 1.71% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 2.5B | ↑ 15.73% |
Total Liabilities | 1.6B | ↑ 32.37% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 159.3M | ↓ 27.71% |
Investing Cash Flow | -116.1M | ↑ 84.24% |
Financing Cash Flow | -50.6M | ↓ 58.03% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 158.2M | ↓ 0.67% |
Investing Cash Flow | -57.2M | ↓ 50.77% |
Financing Cash Flow | -131.2M | ↑ 159.16% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 108.8M | ↓ 31.23% |
Investing Cash Flow | -425.4M | ↑ 644.09% |
Financing Cash Flow | 367.5M | ↓ 380.05% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 172.3M | ↑ 58.32% |
Investing Cash Flow | -86.3M | ↓ 79.7% |
Financing Cash Flow | -15.7M | ↓ 104.29% |
FY23 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 273.1M | ↑ 58.51% |
Investing Cash Flow | -143.8M | ↑ 66.53% |
Financing Cash Flow | -100.4M | ↑ 537.27% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 79.6M | ↑ 23.59% |
Investing Cash Flow | -18.0M | ↓ 50.67% |
Financing Cash Flow | -1.6M | ↓ 96.77% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 19.1M | ↓ 76.03% |
Investing Cash Flow | -15.3M | ↓ 15.24% |
Financing Cash Flow | -598.0K | ↓ 62.69% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 99.1M | ↑ 419.35% |
Investing Cash Flow | -25.1M | ↑ 64.7% |
Financing Cash Flow | -7.2M | ↑ 1099.33% |
Sell
Neutral
Buy
Haemonetics Corp is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Haemonetics Corp | -0.3% | -8.93% | -14.15% | 6.31% | -40.16% |
Intuitive Surgical, Inc. | 6.56% | 41.26% | 91.18% | 53.45% | 177.85% |
Resmed Inc. | -2.51% | 33.07% | 63.68% | -8.76% | 83.88% |
Becton, Dickinson And Company | 3.84% | 4.22% | -4.76% | -1.1% | -4.07% |
Alcon Ag | -2.89% | 18.03% | 30.76% | 16.68% | 62.63% |
Cooper Companies Inc., The | -1.41% | 20.24% | -66.42% | 5.22% | 50.71% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Haemonetics Corp | 34.05 | 34.05 | 1.22 | 3.96 | 0.13 | 0.06 | NA | 17.7 |
Intuitive Surgical, Inc. | 81.54 | 81.54 | 4.08 | 6.65 | 0.16 | 0.08 | NA | 41.4 |
Resmed Inc. | 34.67 | 34.67 | 2.0 | 7.71 | 0.23 | 0.13 | 0.01 | 33.11 |
Becton, Dickinson And Company | 48.07 | 48.07 | 1.11 | 13.11 | 0.06 | 0.03 | 0.02 | 89.5 |
Alcon Ag | 42.58 | 42.58 | 3.58 | 3.06 | 0.05 | 0.03 | 0.0 | 42.35 |
Cooper Companies Inc., The | 59.32 | 59.32 | 11.0 | 3.66 | 0.05 | 0.03 | NA | 39.8 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Haemonetics Corp | Buy | $3.9B | -40.16% | 34.05 | 8.61% |
Intuitive Surgical, Inc. | Buy | $168.3B | 177.85% | 81.54 | 27.65% |
Resmed Inc. | Buy | $35.2B | 83.88% | 34.67 | 21.79% |
Becton, Dickinson And Company | Buy | $69.5B | -4.07% | 48.07 | 7.13% |
Alcon Ag | Buy | $46.6B | 62.63% | 42.58 | 11.44% |
Cooper Companies Inc., The | Buy | $21.3B | 50.71% | 59.32 | 9.45% |
Insights on Haemonetics Corp
Revenue is down for the last 2 quarters, 343.29M → 336.17M (in $), with an average decrease of 2.1% per quarter
Netprofit is up for the last 2 quarters, 20.36M → 38.37M (in $), with an average increase of 46.9% per quarter
In the last 1 year, Intuitive Surgical, Inc. has given 95.3% return, outperforming this stock by 109.8%
In the last 3 years, Intuitive Surgical, Inc. has given 53.4% return, outperforming this stock by 47.1%
Capital Research Global Investors
BlackRock Inc
Vanguard Group Inc
Wellington Management Company LLP
Neuberger Berman Group LLC
State Street Corp
haemonetics is the blood management company. our comprehensive portfolio of integrated devices, information management, and consulting services offers blood management solutions for each facet of the blood management continuum. collectively they help improve patient care, ensure patient safety, and reduce costs for blood and plasma collectors, hospitals, and patients around the world. our mission we believe that through proper blood management, our products and services can help our commercial plasma and blood center customers optimize their collection processes. we seek to help ensure a continual supply of high-quality plasma for biopharmaceuticals and blood components for therapeutic use at optimal costs, along with better blood management processes. working with our hospital customers, we seek to prevent a blood transfusion to the patient who doesn’t need one, or, if a transfusion is necessary, to ensure the transfusion of the right blood product, at the right time, in the right
Organization | Haemonetics Corp |
Employees | 3657 |
CEO | Mr. Christopher A. Simon |
Industry | Health Technology |
International Select Dividend Ishares
$74.79
-1.79%
Vanguard Ultra Short Bond Et
$74.79
-1.79%
Core Scientific Inc
$74.79
-1.79%
Integer Holdings Corp
$74.79
-1.79%
Liberty Global Plc - Class C Shares
$74.79
-1.79%
Pampa Energia Sa
$74.79
-1.79%
Icf International Inc
$74.79
-1.79%
Pacific Premier Bancorp Inc
$74.79
-1.79%
Arbor Realty Trust, Inc.
$74.79
-1.79%